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under investigation with the purpose of efficient local delivery and reduced systemic toxicity but thus far have had limited clinical success. 12 Autologous fat grafting is an emerging technique for reducing contour irregularities associated with breast conservation and for reconstructive surgery following tumor resection. Adipose tissue is harvested from the patient by liposuction techniques and then grafted to the breast. [13] [14] [15] We hypothesized that an antiestrogen could be delivered directly to the resection bed by infusing autologous adipose tissue with a highly lipophilic antiestrogen before its use in reconstructing the defect. It was surmised that local drug concentration could be higher with local delivery of antiestrogens than with systemic therapy alone, which is limited by toxicity. Thus, this delivery method may enhance the efficacy of current systemic therapy and provide an alternative for those who cannot tolerate systemic therapy. In this proofof-principle study, we demonstrate that human adipose tissue harvested by liposuction can be effectively loaded with the antiestrogen fulvestrant, and that the concentration and release of fulvestrant over time is sufficient to inhibit breast cancer cell estrogen receptor activity and proliferation.
MATERIALS AND METHODS

Chemicals and Antibodies
Fulvestrant and β-actin antibody were purchased from Sigma-Aldrich (St. Louis, Mo.). Cyclin D1, estrogen receptor α, and progesterone receptor antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.). All other chemicals were of the highest purity available.
Adipose Tissue Collection
All adipose tissue was collected from women at the University of California, San Francisco, who were already undergoing autologous fat grafting for breast reconstruction. Fat was harvested from the abdomen and upper thighs by means of standard liposuction techniques using a 2.1-mm cannula. The adipose tissue was collected and processed using the Revolve system (LifeCell Corp., Bridgewater, N.J.). The Revolve system collects adipose aspirate, washes it with lactated Ringer's solution at 37°C by gentle agitation with rotating paddles, and then removes excess liquid by vacuum aspiration. Adipose tissue was immediately used in subsequent analyses.
Cell Culture
MCF7 cells (American Type Culture Collection, Manassas, Va.) were maintained in Dulbecco's Modified Eagle's Medium (Fisher Scientific, Atlanta, Ga.) with 10% fetal bovine serum (Sigma-Aldrich), 2 mM glutamine, and 50 unit/ml penicillin and 50 µg/ml streptomycin (Fisher Scientific), referred to as complete medium. Cells were incubated in a humidified atmosphere with 5% carbon dioxide at 37°C.
Tumor Xenografts and Histopathology
Athymic, nude, female mice (n = 5) (Taconic Biosciences, Derwood, Md.) were implanted with a 60-day estradiol pellet and MCF7 cells subcutaneously and bilaterally. MCF7 cells (1 × 10 7 ) alone were implanted on the left flank; on the right flank, MCF7 cells (1 × 10 7 ) mixed with an equal volume of Revolve-processed adipose tissue (100 μl) were implanted. Tumor volumes were calculated using caliper [(length × width 2 )/0.5]. At the conclusion of the experiment, tumors were harvested, formalin fixed, and embedded in paraffin. Hematoxylin and eosin staining was performed by the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center tissue core (supported by National Institutes of Health/National Cancer Institute grant P30 CA82103). Images were captured using a Zeiss PALM microbeam system in conjunction with Axiovision software (Carl Zeiss, Oberkochen, Germany) and processed with Adobe Photoshop software (Adobe Systems, Inc., San Jose, Calif.).
Cell Activity, Proliferation, and Viability Assays
To assess relative activity of adipose tissue or MCF7 cells, a tetrazolium compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay was performed using CellTiter 96 AQueous one solution (Promega, Madison, Wis.). For adipose tissue, the indicated amount of tissue was incubated with 1-ml assay reagent [1:5, CellTiter reagent-to-phosphate-buffered saline (volume/ volume)] at 37°C for 30 to 60 minutes. As a negative control, an equal amount of adipose tissue was lysed by repeated freezing and thawing (four cycles). For MCF7 cells, a 96-well tissue culture plate was seeded with 2 × 10 3 cells. Cells were then treated with the indicated medium for 96 hours. The medium was then removed and cells were incubated with 100-μl assay reagent [1:5, CellTiter reagent-to-phosphate-buffered saline (volume/ volume)] at 37°C for 1 to 2 hours. Absorbance at 492 nm was measured as readout for cellular activity. To determine MCF7 cell proliferation or viability co-cultured with adipose tissue, 1 × 10 5 cells per well were seeded onto 12-well plates. Adipose tissue collected with a 2.1-mm cannula and processed using the Revolve method was mixed 1:1 with complete medium and co-cultured with MCF7 cells for 96 hours. MCF7 cells were then harvested, counted, and evaluated for viability using a trypan blue exclusion assay as described previously. 16 All treatments were conducted in triplicate.
Western Blot Analysis
Western blot analysis of MCF7 cell proteins was conducted as described previously.
16,17
Statistical Analysis
To evaluate the correlation between adipose mass and cellular activity, a Pearson correlation coefficient was calculated and presented as the coefficient of determination (R 2 ). To test the difference between two variables, a t test was performed, with two-sided values of p ≤ 0.05 considered significantly different. Statistical evaluations were performed using SigmaPlot software (Systat, Inc., San Jose, Calif.).
RESULTS
Autologous fat grafting is often used following breast conservation surgery to reconstruct resultant contour deformities. In this proof-of-principle study, we sought to test the feasibility of loading autologous adipocytes harvested from patients with the antiestrogen fulvestrant as a drug delivery vehicle. To assess this concept, we first developed a method for reliably evaluating the viability of adipose tissue. In cell culture models, assays using tetrazolium salts (e.g., MTS) are used for measuring relative viability. To determine whether this assay could be adapted to adipose tissue, the correlation between MTS activity and grams of adipose tissue was examined. We used adipose tissue that was harvested using a 2.1-mm cannula with a Revolve system. The tissue was washed three times with warm saline, with centrifugation (200 g for 5 minutes) and aspiration of liquid between washes. Tissue was aliquoted from roughly 0.025 to 0.2 g and assayed by MTS. A linear correlation between MTS activity and grams of adipose was demonstrated with an R 2 = 0.847 ( Fig. 1) . Furthermore, repeated freeze-thaw cycles of adipose tissue significantly reduced the measured activity (data not shown), demonstrating that conversion of the tetrazolium salt to its measurable product was the result of metabolically active cells and not an artifact of adipose tissue. Thus, evaluating viability with up to approximately 0.2 g of adipose tissue using an MTS assay and normalizing samples by mass was deemed suitable for subsequent sample evaluation.
Autologous Adipose Tissue Does Not Promote Breast Cancer Cell Viability and Tumorigenesis
Concern has been raised about the tumorigenic potential of autologous fat grafting following Plastic and Reconstructive Surgery • September 2017 tumor resection. 18 It has been hypothesized that mesenchymal stem cells and associated stroma of adipose tissue could promote local recurrence by releasing adipokines that induce angiogenesis and proliferation. To evaluate this potential, we first examined the effect of co-culturing adipose tissue with breast cancer cells in vitro. When MCF7 and T47D cells were co-cultured with equal volumes of growth medium and adipose tissue for 96 hours, no significant difference was observed in breast cancer cell proliferation or viability compared to cells cultured without adipose tissue (Fig. 2, left) . We next extended this evaluation in vivo using a mouse xenograft model. MCF7 cells with or without equal volumes of adipose tissue were implanted subcutaneously. As expected, the initial total volume in MCF7 tumors containing adipocytes was larger, demonstrating the viability of adipocytes during the tumor growth period. The tumor volumes (MCF7 cells with or without adipocytes) were not statistically distinguishable beyond the first 2 weeks of growth (Fig. 2, right) , suggesting that the presence of adipose tissue did not promote MCF7 cell tumorigenesis. After 8 weeks of growth, however, there were significant qualitative differences in composition and structure between the tumors that were exposed to adipocyte injection and those that were not (Fig. 3) . Implanted MCF7 cells alone produced dense, highly cellular, dedifferentiated tumors growing devoid of any mammary structure and architecture. In contrast, MCF7 cells co-implanted with adipose tissue resulted in tumors that grew in more duct-like structures, surrounded by adipocytes and the formation of new blood vessels, suggesting a more differentiated tumor. Groups of adipocytes could be seen in vein-like penetrations in the outer third of the tumors (Fig. 3,  below) . In adipocyte-rich regions, "pockets of tumor" cells were observed (Fig. 3, below) , which were surrounded by stroma and often a substantial amount of immune cell infiltration. Furthermore, tumor pockets surrounded by adipocytes often exhibited necrosis. These findings suggest not a tumorigenic effect of adipocytes but possibly increased tumor differentiation and immune cell infiltration.
Adipose Tissue Can Effectively Deliver Fulvestrant to Inhibit MCF7 Cells
Next, we tested whether the lipophilic nature of adipocytes could be used to deliver an anticancer agent and provide a tumor bed treatment boost. Fulvestrant is the most potent antiestrogen; however, its systemic bioavailability is poor and thus not effective for systemic administration in premenopausal women. Unlike tamoxifen and raloxifene, fulvestrant is a pure antiestrogen and does not exhibit proestrogenic effects. Furthermore, the relative lipophilicity of fulvestrant is high (fulvestrant logD, 8.47; tamoxifen logD, 6.122; raloxifene logD, 5.406), and thus should partition in adipose-rich tissue at higher levels. Unlike tamoxifen, fulvestrant does not require metabolism to an active metabolite and thus may be delivered locally. To transfer fulvestrant to tumor cells, adipocytes have to take up sufficient concentrations of fulvestrant and then allow drug release and transfer to tumor cells. Following liposuction, adipose tissue (1 g) was immediately transferred to tissue culture medium containing increasing concentrations of fulvestrant (0, 1, 5, and 25 μM) and incubated at 37°C for 18 hours, rocking continuously. The tissue was then washed thoroughly with saline and adipocyte viability was evaluated (Fig. 4, above,  left) to determine the toxicity of fulvestrant to adipocytes. Incubation with supertherapeutic doses of fulvestrant did not reduce viability of the adipose tissue and appeared to increase the metabolic activity and viability in treated adipocytes (p < 0.05). To determine whether adipose tissue can function as a vehicle for delivery of fulvestrant, fresh tissue (approximately 1 g) was incubated with increasing concentrations of fulvestrant in complete medium for 18 hours at 37°C. Adipose tissue was then washed thoroughly with saline and transferred to a volume of complete medium equal to that used to load fulvestrant and incubated at 37°C for 96 hours to allow for fulvestrant release. Medium containing released fulvestrant was separated from adipose tissue and used to culture MCF7 cells for 72 hours, after which MCF7 cell proliferation and estrogen receptor activity were assessed. Direct treatment of MCF7 cells with 100 nM fulvestrant was sufficient to inhibit cell proliferation (approximately 60 percent) (Fig. 4 , above, right) and down-regulate estrogen receptor expression and activity (Fig. 4, below, left) . Adipose loaded with medium containing 1 μM fulvestrant resulted in sufficient release to inhibit cell growth and expression of the progesterone receptor. Further reductions in estrogen receptor expression and cyclin D1 were seen with higher loading concentrations of fulvestrant (Fig. 4, below, right) .
DISCUSSION
After surgical resection, the risk of breast cancer recurrence is mitigated by radiotherapy and adjuvant hormonal therapy. However, adverse effects related to systematic adjuvant hormonal therapy limit compliance, with fewer than half completing the recommended 5-year treatment course. 10 For women with disease with low metastatic potential, the primary concern is prevention of local recurrence. For these patients, local delivery of hormonal therapy would likely provide a less toxic alternative by avoiding toxicities associated with systemic treatment. Fat grafting is an emerging technique that is used in women with lumpectomy to correct contour deformities. Based on this rationale, we sought to test whether the adipose tissue used in autologous fat grafting could be used to provide local delivery of the antiestrogen fulvestrant. To this end, we have shown that adipose tissue can be loaded with fulvestrant ex vivo. Furthermore, high levels of fulvestrant do not significantly impact adipocyte viability and the fat cells remain viable for reinjection within 18 hours. The release of fulvestrant from adipose tissue is suitable to inhibit estrogen receptor function and breast cancer cell proliferation. 
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Substantial effort has been made to develop novel approaches for the sustained local delivery of therapeutics. For breast cancer, approaches have included implantable hydrogels, wafers, rods, and films that act as depots, 12 which are often designed to biodegrade and thus eliminate the need for surgical removal; topical applications that facilitate transdermal delivery 19, 20 ; intraductal administration 21, 22 ; and iontophoretic devices that use electric fields to drive and direct drug diffusion. 23, 24 An adipose depot has several advantages over these other approaches. It makes use of an increasingly accepted procedure, autologous fat grafting for reconstruction, avoiding the need for an additional procedure and its associated morbidity. Adipose tissue can be loaded within a reasonable time frame, and excessive tissue is generally available even if adipocyte viability after drug treatment is reduced. Novel freezing technologies will allow storage and reloading for repeated procedures. Drug-loaded adipose tissue would be grafted into the resection cavity, maximizing drug contact with the surgical margins and potential residual tumor cells, transforming a corrective technique into a therapeutic intervention. Finally, using autologous tissue as a drug carrier, rather than foreign bodies such as microbeads, minimizes the risk of encapsulation or undesirable immune response, which has been a significant concern for devices designed for local drug delivery.
Several concerns have arisen with the advent of autologous fat grafting for reconstruction of contour deformities following breast cancer tumor resection. A major oncologic concern is the promotion of tumor growth when introducing adipose tissue. 15, 25 Although some studies support this concern, [26] [27] [28] [29] increased risk of breast cancer has not manifested in the clinic. 25, 30, 31 Consistent with clinical findings, we found that coculturing breast cancer cells with adipose tissue for 96 hours did not affect MCF7 proliferation or viability. Furthermore, when co-implanted with adipose tissue in a mouse xenograft, MCF7 cell tumor formation was not significantly affected by the presence of adipose tissue. From these previous studies, it has been shown that experimental context plays a key role. Tumor type, tumor cell line model, adipose tissue processing, and tissue donor all have been shown to affect how adipose tissue influences tumorigenesis. These contextual variances likely all contribute to the difference in our findings compared to others. Furthermore, for this study, whole tissue was used when evaluating the effect of adipose on tumor growth, to best model its application when engrafting following drug loading. This is in significant contrast to most preclinical studies that focus on the influence of the stromal vascular fraction or the further purified adipose-derived stem cells from whole tissue. The stem cell-containing stromal compartment has been shown in vitro and in vivo to promote angiogenesis, metastasis, and tumor cell proliferation in a variety of tumor types. [32] [33] [34] [35] [36] In whole tissue, however, these cells constitute a relatively small fraction and likely exert significantly less progrowth activity, 37 as witnessed in this study. Although proof of concept was demonstrated, significant questions remain regarding the feasibility of translating this approach to the clinic. For example, can the therapeutic dose be regulated and can local delivery of an active dose be sustained to achieve a clinical benefit? Will the presence of drug affect successful engraftment of tissue? Does added time required to load adipose tissue with drug significantly impact the fat grafting procedure and patient care? To demonstrate the robustness of this approach, we are evaluating efficacy with more varied breast cancer models, both in vitro and in vivo, and adipose tissue from multiple donors. Furthermore, quantitative mass spectrometry studies of drug uptake and release are ongoing to characterize the capacity to depot fulvestrant in adipose tissue and to determine the release rate kinetics to assess the potential for sustained therapeutic delivery and dose modification. Finally, we are exploring methods for banking adipose tissue, which may allow tissue initially obtained to be used for multiple engraftments, thus potentially reducing patient burden (e.g., fewer rounds of liposuction and less anesthesia) while providing multiple therapeutic applications.
CONCLUSIONS
In this proof-of-principle study, we demonstrated that adipose tissue intended for autologous fat grafting may act as a vehicle for the local delivery of drug to the breast and moreover to deliver a therapeutic boost to the tumor bed with the possibility of directly impacting residual tumor cells. The increasing use of autologous fat grafting in surgery may provide unique and novel opportunities for this method to transform a predominantly cosmetic approach into a therapeutic intervention by delivering short-term high doses of anticancer agents to the tumor bed to decrease tumor recurrence.
